BioSpace News Archive

Bionomics Limited announced that it will participate in the following upcoming investor conferences in September.

Vivani Medical, Inc., formerly Second Sight Medical, Inc., announced that trading of the Company’s common stock on The Nasdaq Capital Market under the symbol “VANI”.

BIOLASE, Inc., the global leader in dental lasers, announced a strategic plan to partner with postgraduate dental specialty programs throughout North America, to expose new dentists to the benefits of Waterlase technology.

ImmunoGen, Inc. provided an update on the pivotal Phase 2 CADENZA study of pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm.

Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), today announced that it has dosed the first patient in a Phase I trial (NCT 05397041) for its lead product, BMB-101, for the treatment of Dravet Syndrome and other medical indications.

Lannett Company, Inc. (NYSE: LCI) today announced that subject dosing has been completed in the pivotal clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC).

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has entered into a strategic partnership with BioIntelliSense, a continuous health monitoring and clinical intelligence company, for the exclusive U.S. hospital and 30-day post-acute hospital to home distribution rights of the BioButton® multi-parameter wearable for continuous, connected monitoring.

Prelude Corporation (PreludeDxä), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that it has signed an agreement with Galaxy Health Network to provide coverage for the company’s novel DCISionRTâ test for ductal carcinoma in situ (DCIS), also known as stage zero breast cancer.

Evogene Ltd., a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced its financial results for the second quarter ended June 30, 2022.

Biohaven Pharmaceutical Holding Company Ltd. announced the important findings pertaining to the benefit of Nurtec® ODT in decreasing the burden of butalbital use among migraine patients in real world clinical practice.